Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock. Kepler Cheuvreux’s David Evans ...

Global stock markets show mixed weekly performance amid key economic data, tariff tensions, and corporate updates.

Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) owns the other two: Mounjaro and Zepbound. Both Viking and Roche are attempting to horn in on this market, however.

LONDON - The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 ...

Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the ...

U.S. shares in Novo Nordisk, a leading maker of anti-obesity drugs, were down roughly 4% Wednesday afternoon. But shares in Eli Lilly, the other major weight-loss player, were little changed.

Novo Nordisk-aktien er meget mere værd. Det vurderer børshuset Oddo BHF, efter det har haft aktien i den danske medicinalmastodont, der producerer diabetes- og fedmemedicin, under luppen. Novo Nordisk ...